MCID: PSY004
MIFTS: 71

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Psychotic Disorder

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 15
Psychotic Disorders 43 73
Mental or Behavioural Disorder 12
Mental Disorders 73
Psychotic 55

Classifications:

ICD10: 33


Summaries for Psychotic Disorder

MedlinePlus : 43 Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to schizophreniform disorder and delusional disorder, and has symptoms including alexithymia, increased libido and lethargy. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Neuroscience and Circadian entrainment. The drugs Aripiprazole and Asenapine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Related Diseases for Psychotic Disorder

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 33.6 COMT DRD2 NRG1 PRL
2 delusional disorder 32.7 DRD2 DRD3 DRD4
3 traumatic brain injury 31.2 BDNF COMT DRD2
4 brain injury 31.2 BDNF COMT DRD2
5 anxiety 30.8 BDNF COMT HTR2A SLC6A4
6 schizoaffective disorder 30.8 BDNF COMT DAOA DISC1 DRD2 DRD3
7 depression 30.7 BDNF HTR2A RELN SLC6A4
8 asperger syndrome 30.7 DISC1 SHANK3 SLC6A4
9 alexithymia 30.7 COMT DRD2 SLC6A4
10 cocaine dependence 30.5 DRD2 DRD3 SLC6A4
11 paranoid schizophrenia 30.5 BDNF COMT HTR2A SLC6A4
12 borderline personality disorder 30.5 BDNF COMT HTR2A SLC6A4
13 temporal lobe epilepsy 30.3 BDNF RELN SLC1A1
14 post-traumatic stress disorder 30.0 BDNF COMT DRD2 HTR2A MAOB SLC6A4
15 autism spectrum disorder 29.9 BDNF HTR2A RELN SHANK3 SLC6A4
16 alcohol abuse 29.8 BDNF DRD2 DRD3 DRD4 PRL SLC6A4
17 bipolar i disorder 29.5 BDNF COMT DAO DTNBP1 HTR2A NRG1
18 early-onset schizophrenia 29.5 BDNF COMT DRD2 DRD3 DRD4 HTR2A
19 personality disorder 29.4 BDNF COMT DRD2 DRD3 DRD4 HTR2A
20 alcohol dependence 29.4 BDNF COMT DRD2 DRD3 DRD4 HTR2A
21 obsessive-compulsive disorder 29.2 BDNF COMT DRD2 DRD3 DRD4 HTR2A
22 attention deficit-hyperactivity disorder 29.1 BDNF COMT DRD2 DRD3 DRD4 HTR2A
23 mood disorder 28.8 BDNF COMT DAOA DISC1 DRD2 DRD3
24 schizophrenia 28.5 BDNF COMT DAO DAOA DISC1 DRD2
25 autism 28.5 BDNF COMT DISC1 DRD2 DRD3 DRD4
26 disease of mental health 27.7 BDNF COMT DISC1 DRD2 DRD3 DRD4
27 bipolar disorder 27.1 BDNF COMT DAO DAOA DISC1 DRD2
28 drug psychosis 11.0
29 polysubstance abuse 10.9 COMT DRD2 DRD3
30 brunner syndrome 10.9 COMT MAOB SLC6A4
31 obsessive-compulsive personality disorder 10.9 DRD3 SLC6A4
32 hyperprolinemia 10.9 COMT PRODH
33 alzheimer disease 5 10.8 HTR2A SLC6A4
34 schizophrenia 5 10.8 DRD3 HTR2A
35 postpartum depression 10.8 BDNF COMT PRL SLC6A4
36 galactorrhea 10.8 DRD2 PRL
37 fibromyalgia 10.8 COMT HTR2A SLC6A4
38 social phobia 10.8 DRD2 PRL SLC6A4
39 mental retardation, x-linked, syndromic 13 10.8
40 schizophrenia 4 10.8
41 schizophrenia 2 10.8
42 schizophrenia 9 10.8
43 schizophrenia 15 10.8
44 chromosome 2p16.3 deletion syndrome 10.8
45 schizophrenia 18 10.8
46 schizophrenia 19 10.8
47 atypical depressive disorder 10.8 MAOB SLC6A4
48 opiate dependence 10.8 DRD2 DRD3 SLC6A4
49 synucleinopathy 10.8 BDNF COMT MAOB
50 antisocial personality disorder 10.7 COMT DRD2 MAOB SLC6A4

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder

Symptoms & Phenotypes for Psychotic Disorder

UMLS symptoms related to Psychotic Disorder:


alexithymia, increased libido, lethargy, nervousness, numbness, agitation, decrease in appetite, psychiatric symptom, hallucinations, auditory, hallucinations, visual, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, forgetful, feeling jittery, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness, symptoms, sleep disturbances, photophobia, mental and behavioral signs and symptoms, personality changes, catatonic reaction, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.36 PRODH
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.36 PRODH
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.36 PRODH
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.36 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.36 DRD3 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.36 DRD3 DRD4 PRODH
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.36 PRODH
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.36 PRODH

MGI Mouse Phenotypes related to Psychotic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 PRL DISC1 DRD2 PRODH RELN DRD3
2 homeostasis/metabolism MP:0005376 10.16 DAO PRL DISC1 DRD2 PRODH DRD3
3 nervous system MP:0003631 9.89 PRL DISC1 DRD2 PRODH RELN DRD3
4 integument MP:0010771 9.85 PRL DRD2 PRODH RELN RGS4 DTNBP1
5 renal/urinary system MP:0005367 9.17 DRD2 DRD3 RGS4 DTNBP1 MAOB COMT

Drugs & Therapeutics for Psychotic Disorder

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1031)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
2
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
3
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-53-3 2726
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
5
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
6
Linagliptin Approved Phase 4,Phase 1 668270-12-0 10096344
7
Sulpiride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15676-16-1 5355
8 Benperidol Approved, Investigational Phase 4,Phase 2 2062-84-2
9 bromperidol Approved, Investigational Phase 4 10457-90-6 2448
10
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5786-21-0 2818
11
Fluphenazine Approved Phase 4,Phase 3,Phase 2 69-23-8 3372
12
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
13
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-86-8 3559
14 Perazine Approved, Investigational Phase 4 84-97-9
15
Perphenazine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-39-9 4748
16
Pimozide Approved Phase 4,Phase 3,Phase 2 2062-78-4 16362
17
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
18
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 146939-27-7 60854
19
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 298-46-4 2554
20
Coal tar Approved Phase 4,Phase 2,Not Applicable 8007-45-2
21
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3,Not Applicable 28721-07-5 34312
22
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
23
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
24
Zolpidem Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82626-48-0 5732
25
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113-45-1 4158
26
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
27
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
28
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 112111-43-0
29
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68693-11-8 4236
30
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120014-06-4 3152
31
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29110-47-2 3519
32
Curcumin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 458-37-7 969516
33
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
34
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
35
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
36
Reboxetine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 98769-81-4, 71620-89-8 123628 65856
37
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 10118-90-8 5281021
38
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
39
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
40
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
41
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
42
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
43
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 148553-50-8 5486971
44
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
45
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
46
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 93-14-1 3516
48
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
49
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 249296-44-4 5310966
50
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1972-08-3 16078

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
2 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
3 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
4 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Unknown status NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
5 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
6 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
7 Linagliptin and Mesenchymal Stem Cells: A Pilot Study Unknown status NCT02442817 Phase 4 Linagliptin
8 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
9 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Unknown status NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
10 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
11 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
12 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
13 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
14 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
15 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
16 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
17 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
18 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
19 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
20 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
21 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
22 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
23 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
24 Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch Unknown status NCT02697045 Phase 4 Aripiprazole 400mg LAI
25 Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients Unknown status NCT02298985 Phase 4 Curcumin;placebo
26 Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia Unknown status NCT02282085 Phase 4 Aripiprazole Once-Monthly;Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
27 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
28 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
29 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
30 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
31 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
32 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
33 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
34 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
35 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
36 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
37 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
38 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
39 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
40 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
41 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
42 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
43 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
44 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
45 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
46 Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients Unknown status NCT01399450 Phase 4 paliperidone
47 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
48 Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction Unknown status NCT01708837 Phase 4 Propofol
49 Impaired Decision Making in Pedophilic Offenders Unknown status NCT01541150 Phase 4
50 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Psychotic Disorder

Anatomical Context for Psychotic Disorder

MalaCards organs/tissues related to Psychotic Disorder:

41
Brain, Testes, Eye, Heart, Cortex, Skin, Prefrontal Cortex

Publications for Psychotic Disorder

Articles related to Psychotic Disorder:

(show top 50) (show all 403)
# Title Authors Year
1
Cannabis-related psychotic disorder upon relapse to cannabis use: A case series and possible neurobiological implications. ( 29524790 )
2018
2
Mentalizing impairment as a mediator between reported childhood abuse and outcome in nonaffective psychotic disorder. ( 29145104 )
2018
3
No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. ( 29482043 )
2018
4
Auditory steady state response deficits are associated with symptom severity and poor functioning in patients with psychotic disorder. ( 29807805 )
2018
5
Treatment of a Patient with Psychotic Disorder Undergoing Haemodialysis: a Case Report. ( 29864754 )
2018
6
Care Pathways Before First Diagnosis of a Psychotic Disorder in Adolescents and Young Adults. ( 29361848 )
2018
7
Sibling bullying in middle childhood and psychotic disorder at 18 years: a prospective cohort study. ( 29429415 )
2018
8
Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults. ( 29387876 )
2018
9
Evidence that reduced gray matter volume in psychotic disorder is associated with exposure to environmental risk factors. ( 29174764 )
2018
10
Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. ( 29643331 )
2018
11
Is BDNF-Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population-based cohort study. ( 29785763 )
2018
12
Prevalence Rate and Risk Factors of Victimization in Adult Patients With a Psychotic Disorder: A Systematic Review and Meta-analysis. ( 29547958 )
2018
13
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder. ( 29401155 )
2018
14
The development of an occupational therapy intervention for adults with a diagnosed psychotic disorder following discharge from hospital. ( 29721331 )
2018
15
Telephone-delivered psychosocial interventions targeting key health priorities in adults with a psychotic disorder: systematic review. ( 29798730 )
2018
16
Childhood trauma- and cannabis-associated microstructural white matter changes in patients with psychotic disorder: a longitudinal family-based diffusion imaging study. ( 29807550 )
2018
17
Emergence of new-onset psychotic disorder following recovery from LGI1 antibody-associated limbic encephalitis. ( 28363946 )
2017
18
Serum S100B: A proxy marker for grey and white matter status in the absence and presence of (increased risk of) psychotic disorder? ( 28358925 )
2017
19
Abnormal frontoparietal synaptic gain mediating the P300 in patients with psychotic disorder and their unaffected relatives. ( 28345275 )
2017
20
Clinical consequences of extensive routine laboratory investigations in patients with a recent onset psychotic disorder. ( 28162811 )
2017
21
Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. ( 28949339 )
2017
22
Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder. ( 28648915 )
2017
23
Does the Social Functioning Scale reflect real-life social functioning? An experience sampling study in patients with a non-affective psychotic disorder and healthy control individuals. ( 28534464 )
2017
24
Outcome of first-episode acute and transient psychotic disorder in Hong Kong Chinese: a 20-year retrospective follow-up study. ( 27834101 )
2017
25
Cognitive changes in alcohol-induced psychotic disorder. ( 28446210 )
2017
26
Ethnic differences in physician follow-up after a first diagnosis of psychotic disorder. ( 28709775 )
2017
27
Higher required dosage of antipsychotics to relieve the symptoms of first-onset Acute and Transient Psychotic Disorder (ATPD) predicted the subsequent diagnostic transition to schizophrenia: A longitudinal study. ( 28739289 )
2017
28
Insight in body dysmorphic disorder (BDD) relative to obsessive-compulsive disorder (OCD) and psychotic disorders: Revisiting this issue in light of DSM-5. ( 28651226 )
2017
29
A case report of brief psychotic disorder with catalepsy associated with sequential life-threatening events in a patient with advanced cancer. ( 28413438 )
2017
30
Evidence That the Impact of Childhood Trauma on IQ Is Substantial in Controls, Moderate in Siblings, and Absent in Patients With Psychotic Disorder. ( 28177077 )
2017
31
Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorder. ( 28756108 )
2017
32
Clozapine Safety and Efficacy for Interictal Psychotic Disorder in Pharmacoresistant Epilepsy. ( 28632525 )
2017
33
Dopamine D2-receptor affinity of antipsychotics in relation to subjective well-being in patients with a psychotic disorder. ( 28542034 )
2017
34
Quantitative exploration of factors influencing psychotic disorder ailments in Nigeria. ( 28795095 )
2017
35
Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. ( 28517032 )
2017
36
Auditory hallucinations, not necessarily a hallmark of psychotic disorder. ( 28826411 )
2017
37
GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders. ( 28132660 )
2017
38
Treatment of Alcohol-Induced Psychotic Disorder (Alcoholic Hallucinosis)-A Systematic Review. ( 29145545 )
2017
39
Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. ( 28436345 )
2017
40
No Evidence of Association between Childhood Urban Environment and Cortical Thinning in Psychotic Disorder. ( 28045900 )
2017
41
Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. ( 29039260 )
2017
42
Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case-Control Study of the ALSPAC Longitudinal Birth Cohort. ( 29036721 )
2017
43
Antipsychotic treatment and the Rorschach Perceptual Thinking Index (PTI) in psychotic disorder patients: Effects of treatment. ( 28236781 )
2017
44
The details of structural disconnectivity in psychotic disorder: A family-based study of non-FA diffusion weighted imaging measures. ( 28709907 )
2017
45
Length during early childhood and later development of non-affective psychotic disorder. ( 29097001 )
2017
46
Is kidney transplantation safe after careful selection of the recipients with a history of psychotic disorder? ( 29024009 )
2017
47
Intact striatal dopaminergic modulation of reward learning and daily-life reward-oriented behavior in first-degree relatives of individuals with psychotic disorder. ( 29233195 )
2017
48
Outcome of acute and transient psychotic disorder in an index episode: A study from a tertiary care centre in North India. ( 28262127 )
2017
49
Anti-NMDA receptor encephalitis presenting as a primary psychotic disorder. ( 28738102 )
2017
50
Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. ( 28039552 )
2017

Variations for Psychotic Disorder

Expression for Psychotic Disorder

Search GEO for disease gene expression data for Psychotic Disorder.

Pathways for Psychotic Disorder

Pathways related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 12.09 COMT DTNBP1 RGS4 SHANK3 SLC1A1
2
Show member pathways
12.04 COMT DRD2 DRD3 DRD4 MAOB SHANK3
4
Show member pathways
11.74 BDNF DRD2 MAOB
5 11.71 HTR2A MAOB SLC6A4
6 11.64 DRD3 DRD4 HTR2A
7
Show member pathways
11.62 DRD2 DRD3 DRD4
8
Show member pathways
11.32 DRD2 DRD3 DRD4 HTR2A
9
Show member pathways
11.19 DAO MAOB PRODH
10
Show member pathways
10.58 COMT MAOB
11 10.51 COMT MAOB

GO Terms for Psychotic Disorder

Cellular components related to Psychotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 DRD2 DRD3 DRD4 HTR2A NRG1 SLC1A1
2 postsynaptic membrane GO:0045211 9.67 COMT DISC1 DTNBP1 SHANK3
3 postsynaptic density GO:0014069 9.62 DISC1 DRD2 DTNBP1 SHANK3
4 dendritic spine GO:0043197 9.46 COMT DRD2 DTNBP1 SHANK3
5 axon GO:0030424 9.43 BDNF COMT DRD2 DTNBP1 HTR2A NRG1
6 dendrite GO:0030425 9.17 BDNF COMT DRD2 HTR2A NRG1 RELN
7 plasma membrane GO:0005886 10.07 COMT DISC1 DRD2 DRD3 DRD4 DTNBP1

Biological processes related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.87 COMT DRD2 DRD3 HTR2A MAOB MTHFR
2 response to ethanol GO:0045471 9.86 DRD2 DRD3 MAOB
3 response to toxic substance GO:0009636 9.85 DRD2 MAOB SLC6A4
4 cellular calcium ion homeostasis GO:0006874 9.85 DRD3 DRD4 HTR2A
5 locomotory behavior GO:0007626 9.84 DRD2 DRD3 NRG1 SHANK3
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.82 HTR2A NRG1 RELN
7 memory GO:0007613 9.8 BDNF HTR2A SHANK3 SLC6A4
8 modulation of chemical synaptic transmission GO:0050804 9.77 BDNF DRD2 RELN
9 synapse assembly GO:0007416 9.76 BDNF DRD2 NRG1 SHANK3
10 response to amphetamine GO:0001975 9.74 DRD2 DRD3 DRD4
11 learning GO:0007612 9.73 COMT DRD3 RELN SHANK3
12 arachidonic acid secretion GO:0050482 9.72 DRD2 DRD3 DRD4
13 dopamine receptor signaling pathway GO:0007212 9.7 DRD2 DRD3 DRD4
14 response to pain GO:0048265 9.69 COMT RELN
15 positive regulation of neuroblast proliferation GO:0002052 9.69 DISC1 DRD2
16 synaptic transmission, dopaminergic GO:0001963 9.69 DRD2 DRD3
17 positive regulation of long-term synaptic potentiation GO:1900273 9.69 DRD2 RELN SHANK3
18 glial cell differentiation GO:0010001 9.68 NRG1 RELN
19 behavioral response to ethanol GO:0048149 9.68 DRD2 DRD4
20 startle response GO:0001964 9.67 DRD2 NRG1
21 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 DRD2 HTR2A
22 social behavior GO:0035176 9.67 DRD3 DRD4 SHANK3 SLC6A4
23 locomotion GO:0040011 9.66 BDNF SHANK3
24 positive regulation of renal sodium excretion GO:0035815 9.66 DRD2 DRD3
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD2 DRD4
26 prepulse inhibition GO:0060134 9.65 DRD2 DRD3
27 negative regulation of protein secretion GO:0050709 9.65 DRD2 DRD3 DRD4
28 G-protein coupled receptor internalization GO:0002031 9.64 DRD2 DRD3
29 regulation of behavior GO:0050795 9.64 HTR2A RELN
30 neurotransmitter catabolic process GO:0042135 9.63 COMT MAOB
31 dopamine catabolic process GO:0042420 9.63 COMT MAOB
32 positive regulation of AMPA receptor activity GO:2000969 9.62 RELN SHANK3
33 NMDA glutamate receptor clustering GO:0097114 9.62 RELN SHANK3
34 proline catabolic process GO:0006562 9.61 DAO PRODH
35 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.61 DRD2 DRD3
36 acid secretion GO:0046717 9.59 DRD2 DRD3
37 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD2 DRD4
38 negative regulation of dopamine receptor signaling pathway GO:0060160 9.58 DRD2 DRD3
39 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD3 DRD4
40 regulation of locomotion involved in locomotory behavior GO:0090325 9.56 DRD2 DRD3
41 behavioral response to cocaine GO:0048148 9.56 DRD2 DRD3 DRD4 HTR2A
42 regulation of dopamine secretion GO:0014059 9.46 DRD2 DRD3 DTNBP1 HTR2A
43 response to histamine GO:0034776 9.13 DRD2 DRD3 DRD4
44 dopamine metabolic process GO:0042417 8.92 COMT DRD2 DRD3 DRD4

Molecular functions related to Psychotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.56 DRD2 DRD3 DRD4 HTR2A
2 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
4 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Psychotic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed